Connection
Scott Berkowitz to Clinical Trials, Phase II as Topic
This is a "connection" page, showing publications Scott Berkowitz has written about Clinical Trials, Phase II as Topic.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.041 |
|
|
|
-
Solms A, Frede M, Berkowitz SD, Hermanowski-Vosatka A, Kubitza D, Mueck W, Spiro TE, Willmann S, Yan X, Zhang L, Garmann D. Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling. CPT Pharmacometrics Syst Pharmacol. 2019 11; 8(11):805-814.
Score: 0.041